A citation-based method for searching scientific literature

Tzu-Jing Yang, Tian-Neng Li, Rih-Sheng Huang, Max Yu-Chen Pan, Shu-Yu Lin, Steven Lin, Kuen-Phon Wu, Lily Hui-Ching Wang, Shang-Te Danny Hsu. J Cell Biol 2022
Times Cited: 2







List of co-cited articles
2 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Germline BAP1 mutations predispose to malignant mesothelioma.
Joseph R Testa, Mitchell Cheung, Jianming Pei, Jennifer E Below, Yinfei Tan, Eleonora Sementino, Nancy J Cox, A Umran Dogan, Harvey I Pass, Sandra Trusa,[...]. Nat Genet 2011
656
100

Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas.
Yuchen Jiao, Timothy M Pawlik, Robert A Anders, Florin M Selaru, Mirte M Streppel, Donald J Lucas, Noushin Niknafs, Violeta Beleva Guthrie, Anirban Maitra, Pedram Argani,[...]. Nat Genet 2013
476
100

Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma.
Apinya Jusakul, Ioana Cutcutache, Chern Han Yong, Jing Quan Lim, Mi Ni Huang, Nisha Padmanabhan, Vishwa Nellore, Sarinya Kongpetch, Alvin Wei Tian Ng, Ley Moy Ng,[...]. Cancer Discov 2017
415
50

Mutational landscape of intrahepatic cholangiocarcinoma.
Shanshan Zou, Jiarui Li, Huabang Zhou, Christian Frech, Xiaolan Jiang, Jeffrey S C Chu, Xinyin Zhao, Yuqiong Li, Qiaomei Li, Hui Wang,[...]. Nat Commun 2014
248
50

Anatomical, histomorphological and molecular classification of cholangiocarcinoma.
Timothy Kendall, Joanne Verheij, Eugenio Gaudio, Matthias Evert, Maria Guido, Benjamin Goeppert, Guido Carpino. Liver Int 2019
121
50

Cholangiocarcinoma - evolving concepts and therapeutic strategies.
Sumera Rizvi, Shahid A Khan, Christopher L Hallemeier, Robin K Kelley, Gregory J Gores. Nat Rev Clin Oncol 2018
665
50

Clinically significant genomic alterations in the Chinese and Western patients with intrahepatic cholangiocarcinoma.
Shifeng Xu, Yuan Guo, Yanwu Zeng, Zhijian Song, Xiaodan Zhu, Ning Fan, Zhilei Zhang, Guibing Ren, Yunjin Zang, Wei Rao. BMC Cancer 2021
4
50

The spectrum of tumors harboring BAP1 gene alterations.
Yael Laitman, Justin Newberg, Rinat Bernstein Molho, Dexter X Jin, Eitan Friedman. Cancer Genet 2021
7
50

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.
Ethan Cerami, Jianjiong Gao, Ugur Dogrusoz, Benjamin E Gross, Selcuk Onur Sumer, Bülent Arman Aksoy, Anders Jacobsen, Caitlin J Byrne, Michael L Heuer, Erik Larsson,[...]. Cancer Discov 2012
50

Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.
Jianjiong Gao, Bülent Arman Aksoy, Ugur Dogrusoz, Gideon Dresdner, Benjamin Gross, S Onur Sumer, Yichao Sun, Anders Jacobsen, Rileen Sinha, Erik Larsson,[...]. Sci Signal 2013
50


Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Ghassan K Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque, Gina Vaccaro, Davide Melisi, Raed Al-Rajabi, Andrew S Paulson, Mitesh J Borad, David Gallinson, Adrian G Murphy,[...]. Lancet Oncol 2020
506
50

Inference on germline BAP1 mutations and asbestos exposure from the analysis of familial and sporadic mesothelioma in a high-risk area.
Marta Betti, Elisabetta Casalone, Daniela Ferrante, Antonio Romanelli, Federica Grosso, Simonetta Guarrera, Luisella Righi, Simona Vatrano, Giuseppe Pelosi, Roberta Libener,[...]. Genes Chromosomes Cancer 2015
48
50

Cholangiocarcinoma.
Alyssa M Krasinskas. Surg Pathol Clin 2018
62
50

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.
Vivek Subbiah, Ulrik Lassen, Elena Élez, Antoine Italiano, Giuseppe Curigliano, Milind Javle, Filippo de Braud, Gerald W Prager, Richard Greil, Alexander Stein,[...]. Lancet Oncol 2020
142
50

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
Juan Valle, Harpreet Wasan, Daniel H Palmer, David Cunningham, Alan Anthoney, Anthony Maraveyas, Srinivasan Madhusudan, Tim Iveson, Sharon Hughes, Stephen P Pereira,[...]. N Engl J Med 2010
50

Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications.
Miguel A Martin-Serrano, Benjamin Kepecs, Miguel Torres-Martin, Emily R Bramel, Philipp K Haber, Elliot Merritt, Alexander Rialdi, Nesteene Joy Param, Miho Maeda, Katherine E Lindblad,[...]. Gut 2022
5
50

Molecular targeted therapies: Ready for "prime time" in biliary tract cancer.
Angela Lamarca, Jorge Barriuso, Mairéad G McNamara, Juan W Valle. J Hepatol 2020
145
50

Biomarkers for Hepatobiliary Cancers.
Jean-Charles Nault, Augusto Villanueva. Hepatology 2021
59
50

BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways.
Xu-Xiao Chen, Yue Yin, Jian-Wen Cheng, Ao Huang, Bo Hu, Xin Zhang, Yun-Fan Sun, Jian Wang, Yu-Peng Wang, Yuan Ji,[...]. Cell Death Dis 2018
20
50

Novel targeted treatment options for advanced cholangiocarcinoma.
Amit Mahipal, Anuhya Kommalapati, Sri Harsha Tella, Alexander Lim, Richard Kim. Expert Opin Investig Drugs 2018
32
50

Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
J W Valle, I Borbath, S A Khan, F Huguet, T Gruenberger, D Arnold. Ann Oncol 2016
340
50

Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.
Chaitanya R Churi, Rachna Shroff, Ying Wang, Asif Rashid, HyunSeon C Kang, Jacqueline Weatherly, Mingxin Zuo, Ralph Zinner, David Hong, Funda Meric-Bernstam,[...]. PLoS One 2014
283
50

Case Report: BAP1 Mutation and RAD21 Amplification as Predictive Biomarkers to PARP Inhibitor in Metastatic Intrahepatic Cholangiocarcinoma.
Francesco Sabbatino, Luigi Liguori, Umberto Malapelle, Francesca Schiavi, Vincenzo Tortora, Valeria Conti, Amelia Filippelli, Giampaolo Tortora, Cristina R Ferrone, Stefano Pepe. Front Oncol 2020
7
50

Cholangiocarcinoma.
Adeel S Khan, Leigh Anne Dageforde. Surg Clin North Am 2019
76
50

Roles of the BAP1 Tumor Suppressor in Cell Metabolism.
Anna Han, Timothy J Purwin, Andrew E Aplin. Cancer Res 2021
14
50


Intrahepatic Cholangiocarcinoma.
Ramy El-Diwany, Timothy M Pawlik, Aslam Ejaz. Surg Oncol Clin N Am 2019
51
50

Systemic therapies for intrahepatic cholangiocarcinoma.
Robin Kate Kelley, John Bridgewater, Gregory J Gores, Andrew X Zhu. J Hepatol 2020
114
50

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Ghassan K Abou-Alfa, Teresa Macarulla, Milind M Javle, Robin K Kelley, Sam J Lubner, Jorge Adeva, James M Cleary, Daniel V Catenacci, Mitesh J Borad, John Bridgewater,[...]. Lancet Oncol 2020
337
50


Cholangiocarcinoma 2020: the next horizon in mechanisms and management.
Jesus M Banales, Jose J G Marin, Angela Lamarca, Pedro M Rodrigues, Shahid A Khan, Lewis R Roberts, Vincenzo Cardinale, Guido Carpino, Jesper B Andersen, Chiara Braconi,[...]. Nat Rev Gastroenterol Hepatol 2020
567
50

Changing Landscape of Systemic Therapy in Biliary Tract Cancer.
Edward Woods, Dat Le, Bharath Kumar Jakka, Ashish Manne. Cancers (Basel) 2022
4
50

Diversity in cell differentiation, histology, phenotype and vasculature of mass-forming intrahepatic cholangiocarcinomas.
Hiep Nguyen Canh, Kenta Takahashi, Minako Yamamura, Zihan Li, Yasunori Sato, Kaori Yoshimura, Kazuto Kozaka, Minoru Tanaka, Yasuni Nakanuma, Kenichi Harada. Histopathology 2021
4
50

Second-line liposomal irinotecan plus fluorouracil and leucovorin in metastatic biliary tract cancer.
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi. Lancet Oncol 2022
2
50

Oncogenic KRAS Requires Complete Loss of BAP1 Function for Development of Murine Intrahepatic Cholangiocarcinoma.
Rebecca Marcus, Sammy Ferri-Borgogno, Abdel Hosein, Wai Chin Foo, Bidyut Ghosh, Jun Zhao, Kimal Rajapakshe, James Brugarolas, Anirban Maitra, Sonal Gupta. Cancers (Basel) 2021
1
100


Loss of BAP1 Expression Occurs Frequently in Intrahepatic Cholangiocarcinoma.
Juliana Andrici, Benjamin Goeppert, Loretta Sioson, Adele Clarkson, Marcus Renner, Albrecht Stenzinger, Michael Tayao, Nicole Watson, Mahtab Farzin, Christopher W Toon,[...]. Medicine (Baltimore) 2016
44
50

Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).
Jesus M Banales, Vincenzo Cardinale, Guido Carpino, Marco Marzioni, Jesper B Andersen, Pietro Invernizzi, Guro E Lind, Trine Folseraas, Stuart J Forbes, Laura Fouassier,[...]. Nat Rev Gastroenterol Hepatol 2016
664
50

Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study.
Milind Javle, Mitesh J Borad, Nilofer S Azad, Razelle Kurzrock, Ghassan K Abou-Alfa, Ben George, John Hainsworth, Funda Meric-Bernstam, Charles Swanton, Christopher J Sweeney,[...]. Lancet Oncol 2021
58
50


Cholangiocarcinoma.
Paul J Brindley, Melinda Bachini, Sumera I Ilyas, Shahid A Khan, Alex Loukas, Alphonse E Sirica, Bin Tean Teh, Sopit Wongkham, Gregory J Gores. Nat Rev Dis Primers 2021
70
50

Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer.
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi. Expert Opin Investig Drugs 2021
25
50

New Horizons for Precision Medicine in Biliary Tract Cancers.
Juan W Valle, Angela Lamarca, Lipika Goyal, Jorge Barriuso, Andrew X Zhu. Cancer Discov 2017
282
50

Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma.
Bingqi Ma, Huijuan Meng, Ye Tian, Yingying Wang, Tianqiang Song, Ti Zhang, Qiang Wu, Yunlong Cui, Huikai Li, Wei Zhang,[...]. BMC Cancer 2020
34
50

Driver mutations of intrahepatic cholangiocarcinoma shape clinically relevant genomic clusters with distinct molecular features and therapeutic vulnerabilities.
Xiang-Yu Wang, Wen-Wei Zhu, Zheng Wang, Jian-Bo Huang, Sheng-Hao Wang, Fu-Mao Bai, Tian-En Li, Ying Zhu, Jing Zhao, Xin Yang,[...]. Theranostics 2022
5
50

Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
Thomas Boerner, Esther Drill, Linda M Pak, Bastien Nguyen, Carlie S Sigel, Alexandre Doussot, Paul Shin, Debra A Goldman, Mithat Gonen, Peter J Allen,[...]. Hepatology 2021
33
50

Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes.
Carol L Shields, Minoru Furuta, Archana Thangappan, Saya Nagori, Arman Mashayekhi, David R Lally, Cecilia C Kelly, Danielle S Rudich, Anand V Nagori, Oojwala A Wakade,[...]. Arch Ophthalmol 2009
342
50

BAP1 loss defines a new class of renal cell carcinoma.
Samuel Peña-Llopis, Silvia Vega-Rubín-de-Celis, Arnold Liao, Nan Leng, Andrea Pavía-Jiménez, Shanshan Wang, Toshinari Yamasaki, Leah Zhrebker, Sharanya Sivanand, Patrick Spence,[...]. Nat Genet 2012
634
50

Germline BAP1 alterations in familial uveal melanoma.
Karan Rai, Robert Pilarski, Getachew Boru, Muneeb Rehman, Ahmad H Saqr, James B Massengill, Arun Singh, Meghan J Marino, Frederick H Davidorf, Colleen M Cebulla,[...]. Genes Chromosomes Cancer 2017
40
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.